Institut National de la Sant et de la Recherche Mdicale Unit 916, Universit de Bordeaux, Institut Bergoni, Bordeaux, France.
Mol Diagn Ther. 2011 Jun 1;15(3):159-66. doi: 10.1007/BF03256406.
Cisplatin-based adjuvant treatment of non-small cell lung cancer (NSCLC) has become standard, thanks to the studies that have shown a significant survival advantage. The identification of patients who could benefit from this adjuvant treatment would allow ineffective and toxic administrations to be avoided. Immunohistochemical expression of the excision repair cross-complementation group (ERCC)-1 protein has been associated with response to platinum-based chemotherapy in patients with NSCLC, and some polymorphisms of the genes involved in DNA repair have been shown to be associated with survival in advanced NSCLC.
The aim of our study was to evaluate the progression-free survival and tolerability of adjuvant treatment with platinum-based chemotherapy in patients with NSCLC, according to common DNA repair gene polymorphisms and ERCC1 expression.
We investigated the association of three DNA repair gene polymorphisms - Asn118Asn in ERCC1 (rs11615), Lys751Gln in ERCC2 (rs13181), and Asp1104His in ERCC5 (rs17655) - with the progression-free survival of 85 patients treated with platinum-based chemotherapy after surgery for NSCLC.
We did not find significant associations between any of these polymorphisms and progression-free survival, nor did we observe any difference in progression-free survival according to ERCC1 expression.
The previously reported impact of DNA repair gene polymorphisms on platinum-based chemotherapy treatment of advanced NSCLC was not observed in our study in the adjuvant setting.
由于研究表明顺铂为基础的辅助治疗非小细胞肺癌（NSCLC）具有显著的生存优势，因此顺铂为基础的辅助治疗已成为标准治疗。识别可能从这种辅助治疗中获益的患者，可以避免无效和有毒的治疗。NSCLC 患者中 ERCC-1 蛋白切除修复交叉互补组（ERCC）-1 蛋白的免疫组化表达与铂类化疗反应相关，一些涉及 DNA 修复的基因多态性已被证明与晚期 NSCLC 的生存相关。
我们的研究旨在根据常见的 DNA 修复基因多态性和 ERCC1 表达，评估 NSCLC 患者铂类化疗辅助治疗的无进展生存期和耐受性。
我们研究了三个 DNA 修复基因多态性与 NSCLC 手术后接受铂类化疗的 85 例患者无进展生存期的相关性：ERCC1 中的 Asn118Asn（rs11615）、ERCC2 中的 Lys751Gln（rs13181）和 ERCC5 中的 Asp1104His（rs17655）。
我们没有发现这些多态性与无进展生存期之间存在显著关联，也没有观察到 ERCC1 表达与无进展生存期之间存在差异。
在辅助治疗中，我们没有观察到先前报道的 DNA 修复基因多态性对晚期 NSCLC 铂类化疗治疗的影响。
